Starbucks just told its employees that GLP-1s are off the list. It’s part of a disturbing and growing trend of employers dropping GLP coverage.
Drugs like Wegovy, Zepbound, and Saxenda are now gone from the company health plan. If you’re taking one of these medications for diabetes, you’re still covered. If you’re taking it for obesity, you’re now on your own.
The company’s explanation will sound familiar to anyone who’s been following this story. Healthcare costs are climbing fast, and GLP-1s have become one of the biggest line items driving that increase. Starbucks says it remains committed to other benefits, mental health support, preventive care, and wellness programs, but GLP-1s that treat the disease of obesity didn’t make the cut.
Not an Outlier—a Pattern
Starbucks isn’t an outlier here. It’s part of the pattern. A recent survey from the Business Group on Health found that among large employers currently covering GLP-1s for weight management, only 72% expect to keep doing so in 2027. Ten percent say they’re likely to drop it entirely.
A separate Mercer survey found similar numbers, with more employers actively weighing cuts heading into next year. This isn’t a fringe cost-cutting move by one company. It’s a wave.
Employer Math Isn’t Anything Like Girl Math
The reasoning employers give is consistent too. They say the drugs are expensive, and the payoff they were hoping for-fewer bariatric surgeries, lower obesity-related claims down the line-hasn’t shown up in the data yet.
One research group found that 72% of employers cutting coverage are justifying not covering these life-saving meds because of what they’ve labeled high discontinuation rates and weight regain. In other words, many companies are saying they bet on GLP-1s lowering their costs in the long run, and when the numbers didn’t move fast enough, coverage was revoked.
Starbucks hasn’t publicly specified the exact date when it began covering GLP-1 medications for obesity, so it’s difficult to assess if there has even been sufficient time for the benefits of covering the meds to show up in their data. And if you’re wondering if they’ve done the same kind of analysis for any other life-saving medication they cover, such as high blood pressure meds or diabetes drugs, the answer would be no.
What the Spreadsheet Misses
Of course, what gets lost in the company’s math is that the people who are actually taking these drugs to treat obesity aren’t a line item. They’re managing a chronic condition, the same way someone with high blood pressure or high cholesterol manages theirs.
The difference is this treatment costs over a thousand dollars a month before rebates, and now, for a growing number of people, exactly zero dollars of that is covered.
Saying It Plainly
I’m in the pay-out-of-pocket boat myself, so I’ll say plainly what a lot of coverage of this topic tends to dance around. When your employer or insurer decides your treatment doesn’t clear their cost-benefit bar, you don’t stop having the condition. You just don’t have help paying for it.
The decision gets reframed as fiscally responsible, and it is, from a spreadsheet’s perspective. From the patient’s perspective, it’s just a huge bill that didn’t exist last month and does now.
The “Nice to Have” Problem
What frustrates me most about how this story gets told is the implication that this is a “nice to have” perk being trimmed. That it is something optional, a little vanity extra in a bloated benefits package.
To be clear, that’s not what it is for the people actually losing access. It’s the difference between having a treatment plan for your disease and not having one.
The framing matters, because it shapes whether people feel like they’re owed an explanation or should just quietly find $1,000 a month somewhere in their budget.
No Clean Ending
There’s no happy ending or clean resolution to this story. I don’t think this is the last coverage cut we’ll see this year, and I don’t think Starbucks will be the last name in the headlines.
Many people battling obesity will soon find their medication is no longer being covered by their insurance, and like me, they will have to find a way to pay for it out of pocket.
Those who can afford it can purchase their medication directly from the drug manufacturer. But with a high starting price point and a cost that rises with every dosage increase, many will find that option unaffordable.
I choose to purchase my medication through an FDA-regulated compounding pharmacy using a telehealth company. Many other folks may soon find themselves doing the same.
